Literature DB >> 35166939

Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome.

Motoyo Yano1,2, Anup S Shetty3, Greg A Williams4, Samantha Lancia5, Nikolaos A Trikalinos6, Chet W Hammill4, William G Hawkins4, Amber Salter5, Deyali Chatterjee7,8.   

Abstract

OBJECTIVES: To identify PanNEN imaging features associated with tumor grade and aggressive histopathological features.
METHODS: Associations between histopathological and imaging features of resected PanNEN were retrospectively tested. Histopathologic features included WHO grade, lymphovascular invasion (LVI), growth pattern (infiltrative, circumscribed), and intratumoral fibrosis (mature, immature). Imaging features included size, degree/uniformity of enhancement, progressive enhancement, contour, infiltrative appearance (infiltrativeim), calcifications, cystic components, tumor thrombus, vascular occlusion (VO), duct dilatation, and atrophy. Multinomial logistic regression analyses evaluated the magnitude of associations. Association of variables with outcome was assessed using Cox-proportional hazards regression.
RESULTS: 133 patients were included. 3 imaging features (infiltrativeim, ill-defined contour [contourill], and VO) were associated with all histopathologic parameters and poor outcome. Increase in grade increased odds of contourill by 15.6 times (p = 0.0001, 95% CI 3.8-64.4). PanNEN with VO were 51.1 times (p = 0.0002, 6.5-398.6) more likely to demonstrate LVI. For PanNEN with contourill, infiltrative growth pattern was 51.3 times (p < 0.0001, 9.1-288.4), and fibrosis was 14 times (p = 0.0065, 2.1-93.7) more likely. Contourill was associated with decreased recurrence-free survival (p = 0.0003, HR 18.29, 3.83-87.3) and VO (p = 0.0004, HR6.08, 2.22-16.68) with decreased overall survival.
CONCLUSIONS: Infiltrativeim, contourill, and VO on imaging are associated with higher grade/histopathological parameters linked to tumor aggression, and poor outcome.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CT; Imaging; MRI; Pancreatic neuroendocrine neoplasm; Patient outcome; WHO grade

Year:  2022        PMID: 35166939     DOI: 10.1007/s00261-022-03430-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  29 in total

1.  Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival.

Authors:  M Rodallec; V Vilgrain; A Couvelard; P Rufat; D O'Toole; V Barrau; A Sauvanet; P Ruszniewski; Y Menu
Journal:  Pancreatology       Date:  2005-11-29       Impact factor: 3.996

2.  Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated.

Authors:  Hee Sang Hwang; YunJae Kim; Soyeon An; Sung Joo Kim; Joo Young Kim; Sang-Yeob Kim; Dae Wook Hwang; Do Hyun Park; Sang Soo Lee; Song Cheol Kim; Dong-Wan Seo; Seung-Mo Hong
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

3.  A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis.

Authors:  Cherry Kim; Jae Ho Byun; Seung-Mo Hong; Soyeon An; Jin Hee Kim; Seung Soo Lee; Hyoung Jung Kim
Journal:  Abdom Radiol (NY)       Date:  2017-12

Review 4.  Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance.

Authors:  Nam Ju Lee; Ralph H Hruban; Elliot K Fishman
Journal:  Abdom Radiol (NY)       Date:  2018-11

5.  Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases.

Authors:  Salvatore Paiella; Luca Landoni; Roberta Rota; Matteo Valenti; Giovanni Elio; Stefano Francesco Crinò; Erminia Manfrin; Alice Parisi; Sara Cingarlini; Mirko D'Onofrio; Aldo Scarpa; Rita Teresa Lawlor; Laura Bernardoni; Paola Capelli; Chiara Nessi; Marco Miotto; Armando Gabbrielli; Claudio Bassi; Roberto Salvia
Journal:  Endoscopy       Date:  2020-06-04       Impact factor: 10.093

6.  Pancreatic Neuroendocrine Tumors: Computed Tomography Enhancement, But Not Histological Grade, Correlates With Tumor Aggression.

Authors:  Motoyo Yano; Sunil Misra; Danielle H Carpenter; Amber Salter; Charles F Hildebolt
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

7.  Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.

Authors:  Gaspard d'Assignies; Anne Couvelard; Stéphane Bahrami; Marie-Pierre Vullierme; Pascal Hammel; Olivia Hentic; Alain Sauvanet; Pierre Bedossa; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Radiology       Date:  2008-12-18       Impact factor: 11.105

8.  Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour.

Authors:  Adam Johnson; Jesse P Wright; Zhiguo Zhao; Tatsuki Komaya; Alexander Parikh; Nipun Merchant; Chanjuan Shi
Journal:  Histopathology       Date:  2014-10-28       Impact factor: 5.087

9.  Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms: An Analysis of 168 Cases.

Authors:  Deyali Chatterjee; Nikolaos A Trikalinos; Greg A Williams; Jingxia Liu; William G Hawkins; Chet Hammill
Journal:  Pancreas       Date:  2020-02       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.